Introduction: A Disparity in Preventative Medicine
For transgender and gender-diverse (TGD) individuals, the journey toward gender-affirming surgery is often a milestone of identity and physical alignment. Yet, new research from the Boston University Chobanian & Avedisian School of Medicine reveals a sobering reality: many patients are undergoing gender-affirming mastectomies—colloquially known as "top surgery"—without a foundational understanding of how these procedures intersect with their long-term breast and chest cancer risks.
A landmark study published in Breast Cancer Research and Treatment highlights that systemic failures, rather than a lack of intent among providers, are creating a "black box" in oncology care. TGD patients are frequently navigating the healthcare system without knowing their personal genetic predispositions or how their surgical choices might influence future screening requirements. As healthcare institutions grapple with these findings, experts are calling for a fundamental shift in how oncology and gender-affirming care intersect.
The Core Findings: Systemic Failures in Oncology Care
The research team, led by genetic counselor and assistant professor Kim Zayhowski, identified that the primary obstacle is not the incompetence of individual clinicians, but an institutional architecture that was never built to accommodate the nuances of TGD healthcare.
The study indicates that while many surgeons and primary care physicians wish to provide holistic care, the lack of standardized protocols means that cancer risk assessment is often sidelined or entirely absent during the pre-surgical planning phase.
Key Institutional Barriers
- Lack of Standardized Care Pathways: There is no uniform clinical guideline for how to discuss hereditary cancer risk during gender-affirming consultations.
- Fragmented Multidisciplinary Teams: Oncology, genetics, and plastic surgery departments often operate in silos, preventing the seamless integration of genetic counseling into gender-affirming care.
- Ambiguous Accountability: Many institutions fail to designate which department is responsible for discussing long-term cancer screening, leading to the "bystander effect," where providers assume someone else has already addressed the topic.
- Inadequate Education: Both providers and patients lack access to evidence-based resources that explain post-mastectomy screening, particularly for individuals with high-risk genetic mutations like BRCA.
Chronology: A Two-Part Investigative Approach
The findings published in Breast Cancer Research and Treatment are the culmination of a dual-track qualitative research initiative aimed at understanding the "disconnect" in the patient-provider relationship.
Phase 1: The Patient Perspective
In a preceding companion study, researchers interviewed 16 transgender patients who had either undergone or were considering gender-affirming mastectomy. The findings were consistent and alarming: patients reported a systemic lack of information. They often felt that the focus of their surgical consultations was exclusively on the cosmetic or psychological outcomes of the procedure, leaving them in the dark regarding their physiological risk for cancer—specifically whether they carried genetic markers that might have changed their surgical approach (such as opting for a prophylactic mastectomy over a standard gender-affirming procedure).
Phase 2: The Provider Perspective
The current study turned the lens toward 20 healthcare professionals, including oncologists, genetic counselors, plastic surgeons, and primary care physicians. The goal was to understand why these conversations were not taking place. The results confirmed that clinicians are aware of the need for these discussions but feel hamstrung by the absence of formal protocols. Providers expressed frustration at the lack of institutional support, noting that they often feel ill-equipped to guide patients on what screening should look like after chest tissue removal.
Supporting Data and the "Equity Gap"
The urgency of these findings is underscored by broader oncology statistics. Currently, TGD individuals are disproportionately diagnosed with cancer at later, more advanced stages compared to their cisgender counterparts. This disparity is not biological; it is structural.
When a patient undergoes a gender-affirming mastectomy, the amount of breast tissue removed can vary based on surgical technique. However, if that patient carries a genetic mutation that significantly elevates breast cancer risk, standard gender-affirming surgery may not be sufficient as a preventative measure. Without a pre-surgical genetic risk assessment, a patient may be left with residual breast tissue that requires regular, ongoing monitoring—or, conversely, they may have missed an opportunity to perform a risk-reducing mastectomy that could have saved their life.
The research team emphasizes that every person, regardless of their gender identity, deserves clear, actionable data regarding their cancer risk. When this information is withheld—even unintentionally—the patient is stripped of their agency to make truly informed medical decisions.
Official Responses and Expert Insights
Kim Zayhowski, the corresponding author of the study and a specialist in genetic counseling, has been vocal about the need for immediate change.
"Every person—transgender or cisgender—deserves clear information about their cancer risk and access to prevention," Zayhowski stated. "We’re calling on healthcare institutions and organizations to move beyond reliance on individual provider commitment and invest in the institutional infrastructure necessary to guarantee that trans patients receive comprehensive cancer risk information."
The research suggests that the onus should not fall on the shoulders of individual doctors to create their own protocols. Instead, medical centers must treat cancer risk assessment as a standard "check-box" item in the preoperative intake process, much like they would for anesthesia clearance or psychological readiness.
The Path Forward: The CHESTcare Initiative
To bridge the gap identified in their research, the team at Boston University is currently developing CHESTcare (Cancer & Hereditary Risk Education & Support for Transgender and nonbinary individuals).
This digital toolkit serves as a multi-pronged intervention designed to:
- Empower Patients: Provide accessible, non-stigmatizing information about what "risk" means in the context of gender-affirming surgery.
- Educate Providers: Offer clinicians clear, evidence-based workflows for discussing hereditary cancer risks during gender-affirming consultations.
- Facilitate Shared Decision-Making: Create a structured dialogue that ensures both the patient’s gender-affirming goals and their long-term health safety are prioritized equally.
The development of the CHESTcare toolkit represents a shift from identifying the problem to engineering a solution. By standardizing the patient experience, the team hopes to eliminate the confusion that currently clouds the pre-surgical planning phase.
Implications: A Call for Institutional Reform
The implications of this study extend far beyond the operating room. They speak to a broader necessity for "inclusive oncology"—a healthcare model that acknowledges the specific needs of the TGD population without marginalizing them.
Recommendations for Healthcare Systems:
- Integration of Genetic Counselors: Institutions should mandate the inclusion of a genetic counselor in the gender-affirming surgery multidisciplinary team.
- Electronic Health Record (EHR) Updates: Systems should be updated to prompt providers to conduct risk assessments for all patients undergoing chest-related procedures.
- Policy Standardization: Medical associations must collaborate to produce harmonized, evidence-based guidelines that specifically address cancer screening in the context of gender-affirming care.
- Cultural Humility Training: Beyond clinical knowledge, providers must be trained in the sociopolitical factors that affect TGD access to care to build the trust necessary for open, honest communication.
The research from the Chobanian & Avedisian School of Medicine is a clarion call. The healthcare community has made significant strides in providing access to gender-affirming care, but the work is incomplete if that care does not include comprehensive, life-saving cancer risk education.
As the medical community continues to evolve, the focus must remain on the patient’s long-term health trajectory. By investing in the infrastructure and education required to support these individuals, hospitals can ensure that "informed consent" is not just a legal requirement, but a genuine reality for every patient walking through their doors.
Funding for this project was provided by the National Society of Genetic Counsellors Cancer Special Interest Group, signaling a growing industry-wide recognition of the need for this specific type of research.
About the Author
